Organoids are in vitro self-assembling, organ-like, three-dimensional cellular structures that stably retain key characteristics of the respective organs. Organoids can be generated from healthy or pathological tissues derived from patients. Cancer organoid culture platforms have several advantages, including conservation of the cellular composition that captures the heterogeneity and pharmacotypic signatures of the parental tumor. This platform has provided new opportunities to fill the gap between cancer research and clinical outcomes. Clinical trials have been performed using patient-derived organoids (PDO) as a tool for personalized medical decisions to predict patients’ responses to therapeutic regimens and potentially improve treatment outcomes. Living organoid biobanks encompassing several cancer types have been established, providing a representative collection of well-characterized models that will facilitate drug development. In this review, we highlight recent developments in the generation of organoid cultures and PDO biobanks, in preclinical drug discovery, and methods to design a functional organoid-on-a-chip combined with microfluidic. In addition, we discuss the advantages as well as limitations of human organoids in patient-specific therapy and highlight possible future directions.

Keywords: organoids, patient-derived organoid, living biobanks, microfluidics, drug screening, organoids-on-a-chip

INTRODUCTION

Cancer is a heterogeneous disease that includes a complex ecosystem of diverse cell types. Apart from neoplastic cells, tumors include cancer-associated stromal cells, growth factors and metabolites in the microenvironment, which have profound effects on tumor cell growth, invasion ability, and drug response (1). Therefore, these microenvironmental elements are critical in the development of pathologically relevant culture models to study cancer progression. For decades, preclinical cancer research has relied on cell lines as in vitro representations of tumor heterogeneity. Traditional drug development is carried out via two-dimensional (2D) tumor cell line cultures and transplantation of patient-derived tumor xenografts in animals (2). However, there are several drawbacks in these
approaches. For instance, 2D cell line cultures poorly reflect the native microenvironment of tumor tissue, and after many passages in culture, cancer cell lines lose the genetic heterogeneity of parental tumors because of clonal selection (3, 4). This contributes to the low success rate of newly developed drugs in clinical trials (5, 6). Organoids are self-organizing, three-dimensional (3D) structures that are grown in vitro from stem cells, and resemble the organ from which the cells were derived (2, 7). The starting cells could be adult stem cells, cancer stem cell, or cancer tissue-derived spheroids. Organoids preserve many structural and functional features such as cell composition and tissue architecture of their corresponding in vivo organs.

Clevers et al. developed crypt-villus organoids from a single Lgr5+ stem cell using the WENR (Wnt3a+EGF+Noggin+R-spondin-1) protocol that allowed long-term culture and differentiation of primary epithelial cells isolated from intestinal tissue (7–9). The key components of the culture medium included the ligand of LGR5 R-spondin-1, the Wnt pathway agonist, epidermal growth factor (EGF), and bone morphogenetic protein pathway inhibitor Noggin. In addition, the anoikis antagonist Rho-kinase inhibitor Y-27632 is a key factor for improving the success rate of organoid culture. The genotype and genetics of organoids derived from adult stem cells are consistent with those of their parental tissues and remain stable for a long time (10, 11). Another strategy involving the use of pluripotent stem cells (PSCs) has been applied to generate organoids resembling the brain (12), intestine (13), kidney (14, 15) and retina (16, 17).

From 2009 to 2021, use of organoid technology has been rapidly increasing in cancer research, especially for therapeutic screening and precision medicine (18–20). 3D organoid culture systems provide efficient preclinical cancer models of patient-derived organoids (PDOs), can better mimic the components of a tumor tissue, and can be efficiently established from patient specimens (18, 21, 22). The intratumor diversity in PDOs captures tumor heterogeneity at the single cell level and provides a valuable resource for cancer research. PDO cultures can be used to expanded over time while still retaining the mutational profiles of the parental tumors (23). On the contrary, traditional long-term 2D cultures have very high genomic instability. The highly conserved genomic landscape of PDOs is crucial to perform genotype-phenotype correlation analysis and to assess patient’s sensitivity to treatment. Although 2D culture is cheaper and relatively easy to maintain, the success rate of drug screening using 2D cultured tumor cells is very low, and the results are often conflicting. This may be because the 2D model cannot accurately reflect and maintain the tumor characteristics and complex cell-extracellular matrix interactions. Newly developed organoid culture platforms enable routine primary culture of resected human tumor tissues (24, 25). Numerous PDOs have been established from tissues derived from patients’ tumors, including colon (9), liver (25), gastric (26), lung (27), bladder (28), breast (29), and pancreatic cancers (30, 31) and head and neck squamous cell carcinoma (32). PDOs can be used to generate a well-annotated living cancer biobank as a resource for drug discovery and personalized therapy (33, 34). Although there are established PDOs generated from epithelial tissues, PDOs generated from non-epithelial cells are still rare. Sarcomas, malignant neoplasms originating from mesenchymal cells, have a high level of histopathological heterogeneity (35). Currently, several 3D sarcoma models with or without scaffold have been established from osteosarcoma, chondrosarcoma, Ewing sarcoma and soft tissue sarcoma (36–38). However, a standard protocol to generate sarcoma-derived organoid models has not yet been established. Therefore, we expect more advanced innovations to break through the bottleneck of developing sarcoma organoid culture and applications in the future, such as capturing the biological characteristics of native sarcomas in drug screening.

The tumor microenvironment (TME) includes vascular structures, extracellular matrix, and immune cell components, including lymphocytes, macrophages, myeloid-derived suppressor cells, dendritic cells, and natural killer cells (24). Cellular interactions in TME often determine drug response and the fate of the tumor. Functionally, the TME provides conditions for tumor progression and metastasis (39, 40). The recently developed PDO cultures provide an outstanding system to model patient-specific tumor-immune interactions. For instance, the co-culture of patient-derived cancer-associated fibroblasts and peripheral blood lymphocytes with pancreatic cancer organoids has been used to assess lymphocyte migration towards organoids in Matrigel and the activation status of myofibroblast-like cancer-associated fibroblasts (41). Co-culture of non-small-cell lung cancer and colorectal cancer organoids with autologous peripheral blood lymphocytes generates tumor-reactive T cells, and these T cells have the ability to kill tumor cells derived from the parental tumor tissue (20). In addition, culturing patient-derived organotypic tumor spheroids in microfluidic devices preserve endogenous immune cells, and this approach can model the tumor’s response to PD-1 blockade.

With the advancement of technology, many highly reproducible and controllable approaches have been developed to generate the microenvironment of human cancer bioengineered 3D organoid platforms that closely mimic in vivo tumor conditions (42). These platforms, such as organ-on-a-chip, can offer individual empirical data to better determine a patient’s drug response (43). Organ-on-a-chip is a multi-channel microfluidic cell culture device that includes multiple cell types to model the structure and function of the parental tissue (42, 44). Organoids develop from self-organizing stem cells to recapitulate the key physiological and pathological characteristics of their parental tissues. By integrating living human self-organizing organoids with organ-on-a-chip engineering, physiologically relevant microenvironments can be generated, and the resulting organoids-on-a-chip platform can combine the best features of both approaches to provide a model truly representing the complex characteristics of cancer progression (45). As a strategic integration, organoid-on-a-chip technology provides a superior in vitro platform for preclinical screening of chemotherapy drugs and predicting outcomes of radiotherapy and chemotherapy regimens.
In this review, we introduce the experimental approach of deriving organoids from adult stem cells, which can be generated directly from the epithelium of organs and explore how organoid cultures serve as a basis for developing a variety of microfluidic organ-on-a-chip platforms for clinical applications. In addition, we focus on patient-derived tumor organoids (PDTOs) in individualized cancer treatment and illustrate the advantages and limitations of PDTO biobanks as a resource for preclinical models and in enabling precision medicine (Figure 1).

FRONTIER APPLICATION OF PDOs

PDOs in Precision Medicine

Currently, patients with similar cancer types receive cognate treatments, but these treatments do not always achieve a uniform outcome across patient populations. Moreover, regardless of whether patients have undergone neoadjuvant chemoradiation or surgical treatment, individual drug response cannot be tested prior to treatment. In addition, recurring tumors may differ from the initial surgically resected tumors. Despite obvious interpatient heterogeneity, most clinical drugs are not developed using molecular biomarkers, except for some that target specific pathway mutations. To personalize cancer treatment, individual drug sensitivity assays with PDOs are progressively improving by recapitulating more physiological and pathological characteristics of tumors. Therefore, PDOs should be applied to drug screening and guide clinical treatment to improve prognosis. Traditionally, precision therapies have been performed by using mutational biomarkers; however, these biomarkers often lack a considerable tumor mass due to intratumor heterogeneity. As a result, treatments targeting these markers do not always elicit desirable patient responses. PDO models have been utilized in drug discovery (21) to explore the cytotoxicity of therapeutic candidates (46–49) and to enable personalized cancer treatments (18, 50). Recent studies on the generation and use of PDOs are summarized in Table 1 (18, 21, 27–29, 33, 51–62). Using 19 colorectal cancer organoid lines, Van de Wetering et al. screened 83 drugs, including targeted inhibitors (18). Ooft et al. used PDOs to predict the response to chemotherapy in patients with metastatic colorectal cancer, and these results offer a chance to assess the reproducibility and applicability of organoid-based drug screening (63). Sachs et al. tested the response of six drugs targeting the human EGF receptor signaling pathway in 28 organoid lines and confirmed that breast cancer organoids serve as a superior physiologically relevant model for in vitro drug screening (29). Similarly, Yan et al. performed large-scale drug sensitivity screening using 37 anticancer compounds in nine gastric cancer organoids derived from seven patients (33). Vlachogiannis et al. applied patient-derived cancer organoids to predict the clinical outcomes of gastrointestinal cancer patients undergoing chemotherapy, targeted drug therapy and immunotherapy (64). By comparative analysis of the drug sensitivity of patients with metastatic gastrointestinal cancers and that of corresponding PDO models, they showed that the PDO model had a very high accuracy in predicting drug responses (64). Lee et al. screened 50 drugs in organoid models of bladder cancer, expressing the fibroblast growth factor (FGF) receptor, mitogen-activated protein kinase, and the mechanistic target of rapamycin inhibitors (28). Using 27 liver cancer organoid lines from five patients, Li et al. screened 129 cancer drugs and demonstrated that a subset of drugs induced a uniform toxic response across patient samples while the response to other drugs was heterogeneous (60). Pauli et al. performed a complete genomic analysis of four patients and high-throughput screening of 160 drugs using cancer organoids, and showed that 3D cultures are better than 2D cultures in identifying suitable individual or combination drugs for individual patients (21). These cancer organoids were derived from patients with metastatic and primary tumors, including prostate, bladder/ureter, kidney, colon/rectum, brain, pancreas, breast, stomach and esophagus, soft tissue, small intestine, lung, liver, adrenal gland, uterus, ovary, appendix and thyroid cancer. Brandenberg et al. reported an automated high-throughput screening system based on organoid cultures that could analyze thousands of individual gastrointestinal organoids within a polymer-hydrogel substrate (65). This 3D culture system significantly reduced the consumption of expansion reagents and was suitable for large-scale drug screening. Kim et al. reported an effective method for generating a living biobank of 80 lung cancer organoids (27). The drug responses of these organoid lines were consistent with interpatient and intratumor heterogeneity, indicating that cancer organoids are physiologically relevant drug screening platforms. Yao et al. established a living...
organoid biobank of locally advanced rectal cancer and showed that PDOs could predict chemoradiation responses in patients (66). Wang et al. reported a blinded study that found a PDTO model to be accurate in predicting chemotherapy responses in stage IV colorectal cancer (67).

Monoclonal antibodies that target immune checkpoints, such as anti-CTLA4 and anti-PD-1, have been used to enhance anti-tumor T cell responses, increasing the overall survival rate in patients. Nigris et al. reported that PDOs were able to predict the patient’s response to PD-1/PD-L1 inhibitor therapy in primary chordoma (68). Jenkins et al. established a microfluidic culture of an organoid tumor spheroid platform to test the response of patient-derived tumors to immune checkpoint blockade treatment (69). Using a PDO/immune cell co-culture model, Zavros et al. demonstrated that rapamycin blocked the transcriptional regulation of PD-L1 by GLI1 and GLI2, and concluded that it is a valid model to assess immunosuppressive myeloid-derived suppressor cell function (70). These results show that gastric cancer organoids and immune cell co-culture systems can be used to predict patient response to immune checkpoint blockade and CAR-T cell infusion.

A search of ClinicalTrials.gov database from May 2015 to June 2021 revealed organoid-related clinical trials with the purpose of evaluating the probability of PDTO models to accurately predict patients’ responses or resistance to existing chemotherapeutic agents (Table 2). These clinical trials mainly focused on the individualized treatment of patients with various tumors and showed numerous advantages of using PDOs in precisely testing the corresponding patient’s sensitivity to chemotherapy and targeted therapy. In addition, an increasing number of PDO-based clinical trials in recent years suggests a trend towards an increasing reliance on PDOs for clinical decision making in personalized medicine. Nevertheless, clinical trials based on PDO models are still focused on tumors with relatively high morbidity and mortality, such as colorectal cancer, lung cancer, glioma, breast cancer, liver cancer, and pancreatic cancer. Moreover, PDOs are mainly derived from epithelial cells, and organoid culture techniques of non-epithelial cells are relatively immature and cannot be used in clinical trials. Organoid culture can partially reveal interpatient heterogeneity in terms of sensitivity to anti-cancer drugs (71). Thus, it is critical to develop an organoid model system to predict drug sensitivity to estimate diversification in drug responses and reduce misguided selection of remedies in clinical trials. In addition, PDOs can be generated from various cancer patients and exhibit the intratumoral heterogeneity of the parental tumors. Herein, we have emphasized that organoid culture systems, especially PDOs, are suitable for precision medicine, including drug screening and prediction of individual patient’s response. As described above, colorectal cancer, breast cancer, gastric cancer, bladder cancer, liver cancer, and lung cancer organoids have been reported for drug screening and sensitivity. However, the application of conventional PDO models in precision medicine has numerous challenges. Although most tumor PDOs recapitulate the genetic composition of the parental tumor at early passages, the extent of genetic drift or the proportion of genetically stable cells in organoids at later passages has not been fully characterized (21). In addition, the lack of endogenous tumor-associated stromal components remains another key limitation of current organoid methods. Thus, the current PDO model is still unable to reflect all the characteristics of an organ. Although we have many urgent challenges to overcome, the continued development of PDOs incorporating immune and other stromal components may ultimately help actualize the promise of precision cancer therapies.

### Table 1 | Application of Drug Screening with Organoid Culture Platforms

| Cancer Type | Organoid Type | Library | Compounds Tested | Cases Tested | Assay Conditions | Refs |
|-------------|---------------|---------|------------------|--------------|-----------------|------|
| Bladder     | CSC-derived   | Target-known inhibitors + chemotherapy drugs | 50 | 11 | Matrigel | (28) |
| Breast      | CSC-derived   | EGFR/AKT/mTORC pathway inhibitors | 6 | 28 | BME | (29) |
| Breast      | CSC-derived   | CDK4/6 and BCL2 signaling pathway inhibitors | 3 | 3 | BME | (51) |
| Colorectal  | CSC-derived   | Doca taxel, Doxorubicin P4HA inhibitor | 3 | 1 | BME | (52) |
| Colorectal  | CSC-derived   | Target-known inhibitors + chemotherapy drugs | 83 | 19 | BME | (18) |
| Colorectal  | CTOS          | Target-known inhibitors | 71 | 1 | W/O Matrix | (54) |
| Colorectal  | CTOS          | Target-known inhibitors + FDA-approved drugs | 2427 | 2 | W/O Matrix | (55) |
| Endometrium | CTOS          | Target-known inhibitors | 79 | 5 | W/O Matrix | (56) |
| Endometrium | CSC-derived   | Menin-MLL complex inhibitor | 1/278 | 4 | Matrigel | (57) |
| Gastric     | CSC-derived   | Approved anti-cancer drugs | 37 | 7 | Matrigel | (33) |
| Glioblastoma| CSC-derived   | EGFR/PDGFR/Topoisomerase-II inhibitors and p53 pathway activator | 4 | 3 | Collagen-hyaluronic acid bioink | (58) |
| Glioblastoma| CSC-derived   | Target-known inhibitors | 64 | 2 | Matrigel | (59) |
| Liver       | CSC-derived   | NCI-Approved Oncology Drugs Set VII | 129 | 5 | Matrigel | (60) |
| Lung        | CSC-derived   | Target-know inhibitor + chemotherapy drugs | 29 | 5 | BME | (61) |
| Ovarian     | CSC-derived   | PARP /c-Met /EGFR inhibitor + Doca taxel | 4 | 6 | Matrigel | (27) |
| Various     | CSC-derived   | chemotherapy drugs and targeted agents under clinical development | 160 + 120 | 4 | Matrigel | (21) |

CSC, cancer stem cell; CTOS, cancer tissue-originated spheroid; BME, basement membrane extract. Chemo drugs; W/O, Water/Oil.
TABLE 2 | Summary of Clinical Trials of drug sensitivity with organoid methods.

| Tissue Type               | Source of Organoids                                      | Aim of study                                                                                   | Estimated Enrollment | First Posted       | Sponsors/Collaborators                                                                                     | ClinicalTrials.gov Identifier/Status |
|---------------------------|----------------------------------------------------------|------------------------------------------------------------------------------------------------|----------------------|-------------------|------------------------------------------------------------------------------------------------------------|---------------------------------------|
| Astrocytoma               | iPSC from patients’ peripheral blood mononuclear cell    | To demonstrate that brain organoids can be used to test the impact of genetic mutants.          | 20                   | June 3, 2019      | Sponsors and Collaborators: Assistance Publique Hopitaux De Marseille                                    | NCT03971812/ Unknown                  |
| Breast cancer             | breast cancer organ platform                             | Sensitivity Detection and Drug Resistance Mechanism (29 compounds)                              | 300                  | April 24, 2019    | Sponsor and Collaborators: Xijing Hospital, Xi’an, China                                                | NCT03925233/ Enrolling by invitation |
| Breast cancer             | Biopsy of primary or metastatic tumors                   | Drug Sensitivity Verification or Prediction (Paclitaxel)                                        | 50                   | June 1, 2018      | Sponsors and Collaborators: Peking Union Medical College, Beijing, China                                 | NCT03544047/ Unknown                  |
| Bilary Tract Cancer       | Tumor resection                                          | Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring          | 20                   | September 23, 2020| Sponsors: University of Washington Collaborators: Natera, Inc. SEngine Precision Medicine, Inc.         | NCT04561453/ Recruiting               |
| Colon Cancer              | biopsy of RAS/RAF wild-type metastatic right colon cancer tumor lesion | Test the sensitivity and clinical consistency of cetuximab.                                     | 80                   | May 28, 2021     | Sponsor: Danwang Medical Technology (Shanghai) Co., Ltd, China Collaborator: Fudan University, China     | NCT04906733/ Recruiting               |
| Cholangitis/ Cholangiocarcinoma | Cholecystectomy (gallbladder removal); bile and biliary brushings | Characterization of Biliary Cell-derived Organoids                                              | 300                  | February 15, 2021| Sponsors and Collaborators: Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NCT04753996/ Recruiting               |
| Cystic Fibrosis           | Rectal Biopsy and Suction biopsy or forceps biopsy (CF and R334W mutation) | Investigate the response to ivacaftor/tezacaftor in patients with CF and a R334W mutation.    | 30                   | February 5, 2020  | Sponsor: Universite Ziekenhuizen Leuven; Collaborators: Vertex Pharmaceuticals Incorporated KU Leuven University of Lisbon | NCT04254705/ Not yet recruiting      |
| Esophageal Cancer         | Biopsy by diagnostic EUS                                 | Prospective evaluation of chemoradioreistance                                                  | 100                  | September 14, 2017| Sponsors and Collaborators: University Medical Center Groningen, Netherlands                          | NCT03283527/ Unknown                  |
| Familial adenomatous polyposis, Crohn and ulcerative colitis | intestinal biopsies (From Inflammatory Bowel Disease and Intestinal Polyposis Patients) | ISC and organoid characterization                                                              | 120                  | August 22, 2016  | Sponsors and Collaborators: University Hospital, Toulouse, France                                      | NCT02874365/ Recruiting               |
| Glioblastoma              | Tumor biopsy ('left-over' tumor tissue)                  | Explore Resistance Mechanisms                                                                 | 60                   | April 30, 2021    | Sponsor and Collaborators: Maastricht Radiation Oncology, Netherlands                                  | NCT04883996/ Active, not recruiting   |
| Glioma                    | Tumor resection and blood sampling                       | Establishing living biobank                                                                    | 50                   | April 29, 2021    | Sponsor: Maastricht Radiation Oncology Collaborators: Maastricht University Medical Center Zuyderland Medisch Centrum Ziekenhuis Oost-Limburg | NCT04865315/ Active, not recruiting   |

(Continued)
| Tissue Type | Source of Organoids | Aim of study | Estimated Enrollment | First Posted | Sponsors/ Collaborators | ClinicalTrials.gov Identifier/Status |
|-------------|---------------------|--------------|----------------------|--------------|------------------------|---------------------------------------|
| Gut         | Biopsy specimens (patients with and without hypertension who routinely undergo colonoscopy) | Determine if there are fundamental differences in the gut epithelium in hypertension compared to normotension. | 50 | August 4, 2020 | Sponsor: University of Florida, United State Collaborator: National Heart, Lung, and Blood Institute (NHLBI) | NCT04497727/ Not yet recruiting |
| Human Gut Sensory Epithelial Cells | Endoscopic and colonoscopic biopsies | Study the biology of innervated sensory epithelial cells | 50 | September 5, 2016 | Sponsor and Collaborators: Duke University | NCT02888587/ Recruiting |
| Head and Neck Cancer | Constitution of tumor and blood samples | Predicting the response to patients’ treatments | 98 | February 7, 2020 | Sponsors and Collaborators: Centre Francois Baclesse, France | NCT04261192/ Recruiting |
| Intestine | Small intestinal biopsies (A. healthy controls; B. patients with Food intolerances or Food allergy, patients with inflammatory bowel disease, irritable bowel disease, gluten sensitivity, short bowel syndrome) | The effect of nutrient antigens or therapeutic agents | 375 | August 22, 2017 | Sponsors and Collaborators: University of Erlangen-Nürnberg Medical School, Germany | NCT03256266/ Recruiting |
| Kidney Cancer | Tumor resection, Blood and Urine sample | Establish a reliable and effective method to cultivate kidney cancer cells | 20 | April 13, 2020 | Sponsors and Collaborators: Chinese University of Hong Kong | NCT04342286/ Recruiting |
| Lung Cancer | Surgical specimens | Establish long term culturing and bio-banking conditions, and Predict Treatment Response | 30 | April 26, 2021 | Sponsors and Collaborators: Maastricht Radiation Oncology, Netherlands | NCT04859166/ Recruiting |
| Lung cancer | Resection of tumor tissue | Drug response testing | 50 | June 7, 2019 | Sponsors and Collaborators: University Hospital, Geneva, Switzerland | NCT03979170/ Recruiting |
| Lung Neoplasm | Lung Tumor Resection and Circulating Tumor Cells | Creation a living biobank of PDOs from Stage I-IV lung cancer patients; Treatment Response of Organoids | 150 | August 31, 2018 | Sponsors and Collaborators: The University of Texas Health Science Center at San Antonio, United States | NCT039655015/ Recruiting |
| Liver and Pancreatic Cancer | Tumor resection | Develop In Vitro Models of Liver, Biliary and Pancreatic Cancer | 75 | May 7, 2015 | Sponsor: Cambridge University Hospitals NHS Foundation Trust Collaborators: The Gurdon Institute, Ann McLaren Laboratory of Regenerative Medicine, UK | NCT02436664/ Unknown |
| Meningioma | Surgical specimens | Establishment and Characterization of Meningioma PDOs | 30 | July 21, 2020 | Sponsors and Collaborators: Chinese University of Hong Kong | NCT04478877/ Recruiting |
| Multiple Myeloma | Marrow aspirates | Test chemosensitivity in relapsed multiple myeloma | 70 | March 26, 2019 | Sponsor: Wake Forest University Health Sciences Collaborator: National Cancer Institute (NCI), United States | NCT03890614/ Recruiting |
| NSCLC | Surgical specimens and whole blood | High Throughput Screening Device Based on 3D Nanomatrices and 3D Tumors With Functional Vascularization | 100 | April 1, 2021 | Sponsors and Collaborators: University Hospital, Strasbourg, France | NCT04826913/ Not yet recruiting |

(Continued)
| Tissue Type          | Source of Organoids                                                                 | Aim of study                                                                                       | Estimated Enrollment | First Posted         | Sponsors/ Collaborators                                      | ClinicalTrails.gov Identifier/Status       |
|---------------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------------------------------------------------|---------------------------------------------|
| NSCLC               | Resection tissue or biopsy tissue of NSCLC                                         | Drug Sensitivity Correlation Between PDO Model and Clinical Response                             | 100                  | March 5, 2018        | K2 Oncology, Inc., China                                      | NCT03453307/ Recruiting                    |
| NSCLC               | Surgical specimens                                                                  | Drug sensitivity test                                                                             | 100                  | March 5, 2018        | Sponsors and Collaborators: K2 Oncology, Inc., China          | NCT03453307/ Recruiting                    |
| Neuroendocrine      | Biopsy/surgical fresh tissue of gastroenteropancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma. | To use single-cell sequencing technology to explore neuroendocrine neoplasm molecular biological characteristics, tumor heterogeneity and cell subtypes. | 200                  | June 16, 2021        | Sponsors and Collaborators: Fudan University, China           | NCT04927611/ Not yet recruiting            |
| Ovarian Cancer      | Operative specimens                                                                 | Drug sensitivity (standard regimens: chemotherapies and targeted agents)                        | 30                   | February 24, 2021    | Sponsors and Collaborators: Chonqing University Cancer Hospital | NCT04768270/ Recruiting                    |
| Ovarian Cancer      | Tumor biopsy                                                                        | Drug response testing                                                                             | 48                   | September 18, 2020   | Sponsors and Collaborators: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy | NCT04555473/ Recruiting                    |
| Pancreatic Cancer   | EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process; Surgical specimens after neoadjuvant chemotherapy | Check for the reactivity to anti-cancer drugs used as neoadjuvant chemotherapy                   | 300                  | March 2, 2021        | Sponsors and Collaborators: Samsung Medical Center, Korea     | NCT04777604/ Not yet recruiting            |
| Pancreatic Cancer   | FNA and FNB                                                                         | Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids to improve diagnostics and therapeutics | 50                   | June 19, 2019        | Sponsors and Collaborators: Technische Universität München     | NCT03990675/ Recruiting                    |
| Pancreatic Cancer   | EUS-FNA                                                                             | Assess the responses of FDA-approved anti-cancer drugs                                             | 50                   | June 1, 2018         | Sponsors and Collaborators: Ying Lv, China                    | NCT03544255/ Recruiting                    |
| Prostate Cancer     | Biopsies of metastases or primary tumour tissue of pancreatic cancer                | Establishing organoids                                                                             | 30                   | April 17, 2018       | Sponsor: AMC-UvA, Collaborator: Erasmus Medical Center        | NCT03500068/ Recruiting                    |
| Prostate Cancer     | Extended biopsy (metastatic prostate cancer)                                        | Development of the organoid culture technique from metastases from patients with advanced form of prostate cancer | 20                   | May 16, 2019         | Sponsor: Centre Antoine Lacassagne, France, Collaborator: Centre Mediterraneen de Medecine Moleculaire UMR_S-1065 | NCT03952793/ Recruiting                    |
| Rectal Cancer       | Tumor biopsies                                                                      | Establish a biospecimen collection protocol                                                        | 20                   | May 1, 2020          | Sponsors and Collaborators: Duke University                   | NCT04371198/ Recruiting                    |
| Rectal cancer       | Pre-treatment biopsies                                                              | Predicting neoadjuvant chemoradiation sensitivity                                                   | 80                   | July 5, 2018         | Sponsors and Collaborators: Zhen Zhang, Fudan University, China | NCT03577808/ Unknown                      |
| Refractory Solid Tumours | Biopsy of HNSCC, Epithelial Ovarian, colorectal, breast cancer.                   | 15-drug panel screening                                                                            | 35                   | May 29, 2019         | Sponsors and Collaborators: National University Hospital, Singapore | NCT04279509/ Recruiting                    |
| Vaginal Cancer/Cervical Dysplasia/Cervical Cancer | Vaginal Biopsy                                                                      | Primary Organoid Models for Anti-HPV Treatments                                                    | 50                   | February 20, 2020    | Sponsor: Centre Hospitalier Régional d'Orlaides, Collaborators: CNRS - Pr Chantal PICION | NCT04278326/ Recruiting                    |

NSCLC, Non-Small Cell Lung Cancer; HNSCC, Head and neck squamous cell carcinoma; PDOs, Patient-Derived Organoids; EUS, endoscopic ultrasound; AMC-UvA, Academisch Medisch Centrum - Université de Amsterdam; UMCG, University Medical Center Groningen; EUS-FNA, EUS-guided fine-needle aspiration; EUS-FNB, EUS-guided fine-needle biopsy; iPSC, Induced-Pluripotent Stem Cells; FAP, familial adenomatous polyposis.
Combination of PDOs and CRISPR/Cas9 Gene Editing
CRISPR/Cas9 genome editing in PDOs is used to establish transformation models, and eventually, for drug testing in the future. The use of CRISPR/Cas9 gene editing in PDOs has contributed to uncovering the functional basis of diverse oncogene mutations while also helping to correct the causing mutation in human cancers. Kuo et al. established the first human forward genetic modeling of a commonly mutated tumor suppressor gene, ARID1A, using CRISPR/Cas9 genome editing (72). Using this model, they obtained insights into early transformation mechanisms of ARID1A-deficient gastric cancers. Visvader et al. knocked out breast cancer-associated tumor suppressor genes using CRISPR/Cas9 editing to generate PDO model, and showed that the breast cancer organoid can be used for long-term growth (73). Meltzer et al. generated a novel PDO model to recapitulate aberrantly activated Wnt signaling by combining organoids and CRISPR/Cas9 genome editing (74). Using this model, they investigated the effect of an individual signaling alteration to human Barrett epithelial neoplastic transformation. Their research showed that the application of CRISPR/Cas9 genome editing creates an ideal Barrett epithelial PDO model to study ‘driver’ pathway alterations and improve our understanding of human tumorigenesis.

ORGANOIDS-ON-A-CHIP AND 3D BIOPRINTING
Microfluidic Engineering Organoid Culture System
Recent studies of organoids have applied microfluidics and organ-on-a-chip technology in drug screening (75), in an attempt to overcome the shortcomings of organoid culture. Microfluidic cell culture technology has generated 3D culture devices that are now adapted to spheroid-based organotypic cultures and have been used to model organ microenvironments in vitro (76). This technology provides the possibility of precisely controlling the microscale to model physiological conditions and high-throughput approaches. Patient-derived organotypic tumor spheroids can be generated and evaluated within one to two weeks (69, 77, 78). Li et al. reported that the application of an air-liquid interface (ALI) provides sufficient oxygen supply to sustain organoid growth, which supports the generation of epithelial/mesenchymal hybrids without supplementation of exogenous growth factors (79, 80). The long-term 3D culture is a collagen-based ALI tumor organoid culture system that enables to expand the primary gastrointestinal cells as organoids for months (80). The ALI organoid method has been exploited to culture PDOs from normal and tumor specimens, including melanoma, renal cell carcinoma and non-small cell lung cancer (24). ALI PDOs preserves the heterogeneity of the parental tumor as well as the complex cellular network of the TME. Pavesi et al. developed a microfluidic device that could measure the changes in the antitumor efficacy of adoptive T cells in a 3D collagen microenvironment (81). Jung et al. devised a clinically relevant microphysiological microfluidic-based platform for drug sensitivity testing that could form tumor organoids with preserved morphological and genetic characteristics of the primary lung cancer (82). Torabi et al. designed micropatterned surfaces that integrated microfluidics through a hydrogel solution (83). Using the Cassie-Baxter mode, they created a diffusion and transfer pathway between the hydrogel and bulk fluid, providing an excellent option for PDO culture. The microfluidic 3D culture device could help PDOs retain the parenchyma and stroma, and enabled further assessment of new therapeutic modalities and elucidated the mechanism of chemotherapy resistance (24, 82, 84). Nikolaev et al. established a biomaterial microfluidic platform using tissue engineering and cell self-organizing approaches, which induced intestinal stem cells to establish a tube-shaped epithelium. Moreover, they demonstrated that this device could achieve a spatial arrangement similar to the crypt- and villus-like domains of the intestine in vivo (75). Interestingly, the mini-intestine specialized cell type, which is rarely found in conventional organoids and the luminal capability of the bioengineered system was sufficient to maintain long-term host-microorganism symbiosis (Figure 2A).

The combination of microfluidics and cell biology has led to the development of the organ-on-a-chip platform, which is a miniaturized biomimetic system that represents many physiological characteristics of living tissue, such as the 3D microarchitecture composed of multiple tissue types, dynamic mechanical and biomechanical forces, and functional multiple tissue integrations. Microfluidic organ-on-a-chip technology provides the possibility of easily controlling spatiotemporal flow thereby recreating a microenvironment for developing and maintaining the organoid model. Additionally, nutrient supply, shear stress and geometry can be easily controlled in an organ-on-a-chip platform, so that it is important to choose a critical function for this platform which can be achieved by designing a constructible simplified version of the real system. Achberger et al. presented a novel microphysiological model of the human retina, retina-on-a-chip, which included at least seven different essential retinal cell types derived from hiPSCs (85). The platform provided vasculature-like perfusion by microflow control technology and recapitulated the interaction of mature photoreceptor segments in vitro. In addition, they applied the anti-malaria drug chloroquine and the antibiotic gentamicin to reproduce retinopathic side effects and demonstrated the potential of retina-on-a-chip in drug development. Skardal et al. established a single and integrated multi-organoid body-on-a-chip system with a single recirculating perfusion system to maintain the viability and function of organoids derived from human tissue (86). These integrated systems could support six distinct tissue organoid types for at least 28 days, including the liver, cardiac, vascular, lung, testis, and either colon or brain. Interestingly, the six-organoid integrated platform was used to screen the toxicity of drug compounds at clinically relevant doses, and it was demonstrated that the functionality of one organoid influences the response of other organoids (Figure 2B).
Kasendra et al. established a human duodenum intestine chip using organoids and organ-on-chips technology that mimicked intestinal tissue structure and functions and could be used for preclinical drug evaluation (87).

### 3D Bioprinting of PDOs

The construction of organoids still faces several challenges, including incorporation of vascular structures and immune system, precise architecture in space, and breakthrough in scale size. These vascular structures and immune systems can affect PDOs to predict the response of drug. The advantages of 3D bioprinting in biological reconstruction accelerates the process of organoid construction. Daly et al. developed a bioprinting approach to transfer spheroids into self-healing support hydrogels at high resolution, which achieves the precise manipulation of single spheroids and organoids (88). Ayan et al. discovered an "aspiration-assisted bioprinting" approach to improve the precise of biofabrication and bioprinted different biologics, including tissue spheroids, tissue strands, or single cells (89). In addition, Brassard et al. pursued an approach by printing organoid-forming stem cells to form centimeter-scale tissues that comprise self-organized features (90). The combination of 3D bioprinting and PDOs has successfully recapitulated part of the real structure and function of organoids, and achieved long-term expansion and improved drug testing. Kinsella et al. established bioprinting tumor models to maintain PDO sphere culture of gastric adenocarcinoma using hydrogels with alginate and gelatin (91). Bioprinted brain PDOs can be used for individual drug screening in neurological diseases. Using embedded 3D bioprinting and photocrosslinkable bioink, Shin et al. exploited a 3D brain-like co-culture construct that was composed of heterogeneous neural populations with neurospheres and glia (92). The study showed that the engineered brain organoid exhibited the capability to differentiate into neuronal cells, and the platform may be used to model neurological disease and drug discovery. The use of 3D bioprinting platforms to generate and culture organoids can improve reproducibility to a certain extent and promote the standardization of protocols. Although 3D bioprinting has been used in many organoid platforms, it still has numerous challenges, such as precise construction, printing speed, and suitable biomaterials. First, there is a gap in scale between organoids and actual organs: organoids are only up to a few cubic millimeters in size, which is a million times smaller than actual organs. Second, the long duration of the current manufacturing process may lead to hypoxia related damage by interrupting the continuous supply of nutrients and oxygen levels in the culture system. In addition, a single vasculature is insufficient for organoid development in the later stages of 3D printing organoid culture. Third, although bioprinting technology can effectively control the precise arrangement of cells, a precise construct is still difficult to achieve. Although challenges remain in the bioprinting organoid field, printable bioink and bioprinting strategies will be further developed in the future. Biomaterials, cell and matrix components of organoids, and the scale of organoids is the same as that of an organ. With breakthroughs in bioprinting organoid technologies and microfluidic culture systems, these challenges will be overcome and 3D organ bioprinting will eventually be realized.

**FIGURE 2 | (A) A “mini-gut” organoid model is established in a microdevice containing 3D hydrogel. This microdevice guides self-organizing intestinal stem cells into functional organoids-on-a-chip. [Cited from (75)]. (B) A bioengineered six-organoid integrated platform is generated by microfluidically linked chambers, each containing liver, cardiac, lung, endothelial, testis, and brain organoids. Capecitabine treatment of a system containing liver, results in cytotoxicity in cardiac and lung organoids. Expectedly, this platform without liver organoids does not show significant toxicity. Green, Calcein AM-stained viable cells; Red, Ethidium homodimer-stained dead cells. PMMA, poly (methyl methacrylate); DST, double sided tape. Scale bars, 100 μm. [Adapted from (86)].**
ORGANOID BIOBANKING AND ETHICAL CONCERNS

Living Organoid Biobanks

For individualized cancer treatment, a bridge between clinical practice and translational research is urgently needed. Personalized therapies are based on the molecular and histopathological features of each patient’s tumor. In addition to traditional tissue and biomolecular-based biobanks, the establishment of a “living organism biobank” is receiving increasing attention, and one of its representatives is organoid biobanks. PDOs can be passaged and cryopreserved, providing a chance to establish living biobanks with higher clinical relevance to the patients. PDO libraries allow in-depth investigation of tumor characteristics in vitro. Organoid biobanks, combined with drug sensitivity testing and next-generation sequencing, now support clinical decision-making and clinical trial performance analysis (Figure 3). Van de Wetering et al. first established a living colorectal cancer organoid biobank and described that the organoid culture platform can be exploited for genomic and functional research at the level of the individual patient (18). They provided detailed characterizations of a colorectal cancer biobank, including whole-exome sequencing, copy number analysis, histology and drug screening. Meanwhile, Geurts et al. described a cystic fibrosis intestinal organoid biobank, representing 664 patients (93). In addition, Fujii et al. generated a colorectal cancer organoid biobank that included 52 tumor subtypes and discovered that several organoids obtained new genetic mutations during passage, indicating that current research has not completely avoided the genetic instability of cancer organoids during long-term passage (94). These experimental results show the enormous potential of large-scale PDO biobanks that represent hereditary diseases. Sachs et al. established a living biobank of over 100 breast cancer organoid lines from a wide variety of primary and metastatic tumors (29). Moreover, they analyzed breast cancer organoids to characterize various profiles by large-scale sequencing and drug screening and generated a well-defined living biobank. These analyses ensured that the characteristics of breast cancer organoids were consistent with those of normal and tumor tissues from patients. These results indicated that PDO biobanks are more suitable for rare human cancer subtypes that are difficult to establish as immortalized cell lines. Yan et al. generated a gastric cancer organoid biobank derived from normal, dysplastic, cancer, and lymph node metastatic patients, and it retained different molecular subtypes (33). This biobank preserved features such paired tumor tissue germline DNA information, which is critical for future reference and prediction of patient responsiveness and sensitivity to anti-tumor treatments. Amieva et al. proposed a protocol to rapidly establish apical-out polarity and maintain the integrity and secretory function of epithelium (95). This protocol provides a tool for establishing a living gastrointestinal organoid biobank that can be used to study the impact of host-microbe interactions on epithelial function. Beato et al. established a living biobank of organoids from 15 patients with intraductal papillary mucinous neoplasms (IPMN) of the pancreas (96). These PDOs recapitulated the molecular and histopathological characteristics of the parental IPMN tumors, and the success rates for organoid generation from IPMN tumors and normal pancreatic tissues were similar to those of previous reports wherein the success rates were up to 80% and 87%, respectively (30, 31, 97–99). Jacob et al. reported the generation of patient-derived glioblastoma organoids that were suitable for constructing a biobank and modeling immunotherapy responses. With the complexity of cancer types dictates the outcome, the key...
advantage of these biobanks is that they provide cancer organoid cultures representing the complexity of different tumor subtypes. These cancer and normal organoids accurately reflect patient’s sensitivity to drugs and their tolerance to drug toxicity. An increasing number of cancer biobanks has been reported, but most of the existing organoid culture protocols are only suitable for epithelial carcinomas. As we have described, only a few living tumor biobanks have been established by PDO technology, including colorectal cancer, breast cancer, gastric cancer and glioblastoma. In addition, fewer non-epithelial cancer-derived organoids have been established, such as glioblastoma (100) and childhood kidney cancers (34). Therefore, the generation of more organoid cultures from non-epithelial cancers should be promoted in the future. Based on the current status, more exploration should be performed to obtain living biobanks of rare tumor organoids. In addition, standardization of organoid production is needed to control the quality of PDOs, to improve the reproducibility and scalability, and to avoid the diversity of organoids. Based on the current research status, PDOs cannot fully recapitulate the natural characteristic of the parental tumor, which results in many uncertainties for the promotion of innovative clinical applications of living biobanks in the future.

Ethical Concerns of PDO Research

Although advances in 3D models allow for more complex products to be generated from human tissues, the progress of human organoids may be hindered by ethical concerns. Vasiliki Mollaki analyzed several serious challenges posed by organoid use and biobanking and provided many unique and profound insights to promote the healthy development of organoid research and application (101). He provided an in-depth discussion on ethical challenges in organoid use, which includes the source of stem cells, informed consent of cell donors, issues specific to brain organoids and multi-organoid complexes, gene editing, creation of chimeras, organoid transplantation, commercialization of organoids, patentability of organoids, treatment costs, issues of equity, misuse and dual use of organoids, and organoid biobanking (101). His main suggestion is the four-step approach to help increase the biomedical and social benefits of organoids: the first is related to existing regulations and guidelines, the second is related to special regulatory provisions, the third is public engagement and the fourth is continuous monitoring of rapid advancements.

Organoid biobanking and issues specific to brain organoids are our main concerns. As mentioned above, living organoid biobanking provides an important source for promoting the development of translational research. PDOs have an inevitable connection with the donor’s body, identity, and privacy, among others, which involves human rights issues of the donor, and should differ from the tissues and organs directly derived from the human body. However, there are no binding principles or legal norms defining the rights and duties of donors and biobankers. Organoids are also a technology and a tool; hence, with the increasing commercialization of human organoid-related products, more and more ethical challenges have begun to emerge, especially in drug development, preclinical prediction of patient drug responses, and toxicology testing (102). The conventional frameworks are inapt to capture the practical and ethical complexity of human organoid products. Lensink et al. indicates that commercialization of PDO biobanks raise challenges associated with commercial involvement, trust, and ownership (103). By conducting 21 semi-structured qualitative interviews, they indicated that academia, clinical care, biobanks and industry stakeholders do not belong to distinct domains, and suggest that participants should be regarded as “partner” rather than passive tissue or service providers. These efforts are aimed at establishing an ecosystem that maintains a sound balance between ongoing cooperation and a feasible and sustainable research climate, while making governance more responsible and fair. In addition, living organoid samples can be stored for a long time after being collected and cultivated, even longer than the lifespan of the donor, and follow-up research often fails to provide informed consent. At the current stage of organoid biobanking, there are no standardized and individualized informed consents that can cover all the specific concerns of donors, such as personal values and beliefs. Therefore, opt-out options should be available to allow donors to object to certain uses. In any case, the consent procedure is the central tenet of organoid biobank management to ensure the implementation of the principle of a voluntary and well-informed donation (101).

The ethical issues of special living biobank samples, such as brain organoids, should also draw our attention. The human brain organoid system has already been applied to modeling neurological diseases, including microcephaly, macrocephaly, autism, Miller-Dieker syndrome, Rett syndrome, Sandhoff disease, prenatal drug exposure, ZIKA virus infection, and neurodegenerative diseases (104). Trujillo et al. developed human cortical organoids to model early human brain network development and achieved complex oscillatory waves (105). Reardon et al. discussed the sentient states of brain organoids, and pointed out that a conscious brain should display a much more complex, unpredictable electrical activity than an unconscious one, which responds in simple and regular patterns (106, 107). Although brain organoids do not have neurological functions, these miniature organs constitute neural entities of human origin. Currently, most scientists and ethicists agree that consciousness has not been created; however, with the continuous advance of technologies, brain organoids may be induced to develop consciousness, sensation, and cognition, thus possessing characteristics related to human morality. Therefore, ethical stakes are much more complex than those of other organs. Hyun et al. provided their opinions on the ethics of brain organoids (108). They indicated that brain organoids lack the sensory inputs and a complex network structure and, thus, declared that peoples’ concerns about the moral status might be excessive. At the current stage of development, the degree at which brain organoids exhibit human consciousness is difficult to determine, and neuroscientists have not reached a consensus on the definition and measurement of consciousness. However, if the brain organoids could feel pain, the principles of animal welfare...
would be imposed at least. In addition, the informed consent still should be modified to prepare for the day when brain organoids will be conscious, because the existing informed consent does not reflect all possible connections between the cell donor and brain organoids. Boers et al. proposed a “consent for governance” model that includes privacy by design, participant engagement, benefit sharing and ethical oversight, which contributes to responsible innovation and clinical translation (102). Overall, conventional bioethical frames are inept in addressing the practical and ethical complexities of PDOs. Therefore, it is essential to develop binding legal norms that overcome most of the ethical dilemmas in this exciting field.

DISCUSSION

Models of 3D tumor spheroids preserve cell-cell contact and cell-matrix interaction, present a more clinically relevant resistome and improve the success rate of drug screening (109). Studies have shown that the gene expression profiles of 3D cancer spheroids are different from 2D cultures, recapitulating various features in genes associated with proliferation, survival and drug sensitivity (110). Tumor spheroids embedded in ECM preserve most characteristics of cell biology associated with cell-matrix interrelations, including interaction with basement membranes and interstitial matrix (111, 112). Therefore, despite higher cost compared to 2D cell culture models, 3D tumor spheroids are popular for drug screening and response testing. Current 3D culture tumor models include organotypic multicellular spheroids (from cancer cell lines), tumor-derived organoids (from dissociated tumor tissues) and multicellular tumor spheroids (from cancer cell lines) (113).

Traditional spheroid culture models involve supplementation with B27, EGF, and FGFs. Organoid culture supplements depend on the type of tissue, and major supplements include the Wnt pathway agonist, Rspo1, nicotinamide, N-acetylcysteine, FGFs, noggin and molecule inhibitors (9, 66, 114–116). PDOs recapitulate the intercellular interactions and the characterizations of histology and enable long-term cultivation and stable passage (117). Therefore, PDOs mimic the genotype and phenotype of parental tumor and effectively retain patient-specific tumor heterogeneity, which make them superior to traditional spheroid models for drug screening. However, there are several disadvantages with PDO models that need to be overcome, including high cost and the potential effect of matrix on therapeutic responses. In addition, one main concern in cancer treatment is intra- and intertumoral heterogeneity (118), which can result in inaccurate decision-making and partial treatment benefits. Organoids derived from a portion of a tumor just match the genomic portrait of that particular tumor region, and may not represent the genome map of the entire tumor. Therefore, organoid assays of tumors in vitro should take the spatial tumor heterogeneity into consideration. In addition, owing to patient diversity and varying spheroid culture protocols, the outcome may vary by the laboratory. Culture protocols should be formulated that are specific and standardized for organoids derived from individual organs.

Although PDO models mimic some key aspects of human tumorigenesis, they cannot fully recapitulate the complicated structure of the TME. Tumorigenesis and drug resistance are not only driven by gene alterations in the tumor cells but are also affected by the components of the TME, such as blood vessels, neurons, fibroblasts and immune cells. First, immune system could be polarized to contribute to tumor development during progressive growth phase. Therefore, effort has been made to rejuvenate the anti-tumor immune response in organoid culture systems. Intestinal epithelial organoids have been co-cultured with lymphocytes and macrophages, and showed a significant dynamic movement and continued proliferation activity (75, 119).

As presented in the previous section, PDOs can predict the response of cancer patients to chemotherapy. However, these studies have several limitations. First, owing to the lack of an integral microenvironment, organoid models cannot mimic immunotherapy and antiangiogenic therapy. Second major limitation of the current protocols for organoid culture is the inability to part with animal-derived Matrigel or collagens. These extracellular matrices contain undetermined extracellular components, which may unexpectedly modify biological cell behavior. Third, organ-on-a-chip organoids are suitable for studying the mechanism of tumor metastasis. However, multorgan metastasis has not yet been achieved in organoid models. Additionally, current cancer organoid cultures do not replicate accurate mechanical control and physical manipulations that occur in vivo. Engineered extracellular matrix has been reported, which, however, still cannot meet the requirements of fully functional organoids (120).

Organoids are less expensive than mouse models, but they are relatively expensive compared to traditional cell line models. The time required to establish an organoid model is a few weeks which is less than that in animal models but is still longer than in cell line models. High-throughput assays are required to decrease the time and cost of organoid generation as well as the input material needed to establish the culture. In this regard, microfluidic 3D culture has generated spheroid-based organotypic culture devices. Organoid-on-a-chip is also a microfabricated microfluidic culture platform that combines extracellular matrix and microstructures to simulate one part of the cytoarchitecture and tissue function (42). However, the microfluidic system cannot replicate the interactions between the tumor and the immune network that occurs in situ and is required for an accurate prediction of immunotherapy response ex vivo. Moreover, although intestinal organoid fragments on hydrogel have been applied to manufacture organoid arrays (65, 121, 122), they are not adequate to provide fully automated organoid culture for high-throughput assays. Finally, the generation of organoids and other human tissue products leads to ethical challenges, including gift versus market systems especially during the commercialized exchange of organoids, and the awakening of consciousness in brain organoids.

CONCLUSION

Despite the remaining challenges, PDOs have a higher physiological and pathological relevance than traditional models, and human cancer organoid assays have great
potential in guiding personalized therapies. Meanwhile, PDTOs allow to reliably preserve the molecular, cellular, and histopathological phenotypes of parental tumors and retain patient-specific tumor heterogeneity. Furthermore, organ-on-a-chip has been applied to organoids to accomplish physiological or pathological model systems that are closer to the state of the tissue in vivo. Future advancements in organoid technologies are anticipated to achieve a comprehensive cancer model system that recapitulates physiological conditions by integrating tumor parenchyma cells, vascular and immune cellular networks, and non-cellular TME. This robust model will provide a powerful tool for biomarker research, drug screening, and a more accurate prediction of therapeutic efficacy and eventually improve human health.

AUTHOR CONTRIBUTIONS

The concept of the manuscript was originated by ZZ and XC. The original manuscript was written by ZZ, with additions to the manuscript provided by LC. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the Science and Technology Development Project of Jilin Province (20210402030GH, 20200601010JC, 2021C017, 20210204150YY).

REFERENCES

1. Elia I, Haigis MC. Metabolites and the Tumour Microenvironment: From Cellular Mechanisms to Systemic Metabolism. Science (2021) 3:1(1):21–32. doi: 10.1038/s42255-020-00317-2
2. Tuveson D, Clevers H. Cancer Modeling Meets Human Organoid Technology. Science (2019) 364(6444):952–5. doi: 10.1126/science.aaw6985
3. Birgersdotter A, Sandberg R, Ernberg I. Gene Expression Perturbation In Vitro –A Growing Case for Three-Dimensional (3D) Culture Systems. Semin Cancer Biol (2005) 15(5):405–12. doi: 10.1016/j.semcancer.2005.06.009
4. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor Stem Cells Derived From Glioblastomas Cultured in bFGF and EGF More Closely Recapitulate the Phenotype and Genotype of Primary Tumors Than Do Serum-Cultured Cell Lines. Cancer Cell (2006) 9(5):391–403. doi: 10.1016/j.ccr.2006.03.030
5. Kamb A. What’s Wrong With Our Cancer Models? Nat Rev Drug Discovery (2005) 4(2):161–5. doi: 10.1038/nrd1635
6. Caponigro G, Sellers WR. Advances in the Preclinical Testing of Cancer Therapeutic Hypotheses. Nat Rev Drug Discov (2011) 10(3):179–87. doi: 10.1038/nrd3385
7. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 Stem Cells Build Crypt-Villus Structures in In Vitro Without a Mesenchymal Niche. Nature (2009) 459(7244):262–5. doi: 10.1038/nature07935
8. Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, van den Born M, et al. Paneth Cells Constitute the Niche for Lgr5 Stem Cells in Intestinal Crypts. Nature (2011) 469(7340):415–8. doi: 10.1038/nature09637
9. Sato T, Stange DE, Ferrante M, Vries RGI, van Es JH, van den Brink S, et al. Long-Term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett’s Epithelium. Gastroenterology (2011) 141(5):1762–72. doi: 10.1053/j.gastro.2011.07.050
10. Blokzijl F, de Ligt J, Jager M, Sassiell V, Roerink S, Sasaki N, et al. Tissue-Specific Mutation Accumulation in Human Adult Stem Cells During Life. Nature (2016) 538(7624):260–4. doi: 10.1038/nature19768
11. Serra D, Mayr U, Boni A, Lukanin I, Rempf M, Challet Meylan L, et al. Self-Organization and Symmetry Breaking in Intestinal Organoid Development. Nature (2019) 569(7754):66–72. doi: 10.1038/s41586-019-1146-y
12. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral Organoids Model Human Brain Development and Microcephaly. Nature (2013) 501(7467):373–9. doi: 10.1038/nature12517
13. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, et al. Directed Differentiation of Human Pluripotent Stem Cells Into Intestinal Tissue In Vitro. Nature (2011) 470(7332):105–9. doi: 10.1038/ nature09691
14. Yaguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H, et al. Redefining the In Vivo Origin of Metanephric Neprhon Progenitors Enables Generation of Complex Kidney Structures From Pluripotent Stem Cells. Cell Stem Cell (2014) 14(1):53–67. doi: 10.1016/j.stem.2013.11.010
15. Takasato M, Er PX, Becroft M, Vanslambrouck JM, Stanley EG, Elefanty AG, et al. Directing Human Embryonic Stem Cell Differentiation Towards a Renal Lineage Generates a Self-Organizing Kidney. Nat Cell Biol (2014) 16(1):118–26. doi: 10.1038/ncb2894
16. Eiraku M, Takata N, Inohashi H, Kawaoka M, Sakakura E, Okuda S, et al. Self-Organizing Optic-Cup Morphogenesis in Three-Dimensional Culture. Nature (2011) 472(7341):51–6. doi: 10.1038/nature09941
17. Nakano T, Ando S, Takata N, Kawaoka M, Muguruma K, Sekiguchi K, et al. Self-Formation of Optic Cups and Storable Stratified Neural Retina From Human ESCs. Cell Stem Cell (2012) 10(6):771–85. doi: 10.1016/j.stem.2012.05.009
18. van de Wetering M, Francis HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective Deriving of a Living Organoid Biobank of Colorectal Cancer Patients. Cell (2015) 161(4):933–45. doi: 10.1016/j.cell.2015.03.033
19. Drost J, Clevers H. Organoids in Cancer Research. Nat Rev Cancer (2018) 18(7):407–18. doi: 10.1038/s41568-018-0007-6
20. Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, et al. Generation of Tumor-Reactive T Cells by Co-Culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell (2018) 174(6):1586–98.e112. doi: 10.1016/j.cell.2018.07.009
21. Pauli C, Hopkinds BD, Prandi D, Shaw R, Fedrizzi T, Shoner A, et al. Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discov (2017) 7(5):462–77. doi: 10.1158/2159-8290.cd-16-1154
22. Schutgens F, Clevers H. Human Organoids: Tools for Understanding Biology and Treating Diseases. Ann Rev Pathol (2020) 15:211–34. doi: 10.1146/annurev-pathmedich-012419-032611
23. Artegiani B, Clevers H. Use and Application of 3-D Organoid Technology. Hum Mol Genet (2018) 27(R2):R99–1107. doi: 10.1093/hmg/ddy187
24. Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell (2018) 175(7):1972–88.e16. doi: 10.1016/j.cell.2018.11.021
25. Nuciforo S, Fofana I, Matter MS, Blumer T, Calabrese D, Boldanova T, et al. Organoid Models of Human Liver Cancers Derived From Tumor Needle Biopsies. Cell Rep (2018) 24(5):1363–76. doi: 10.1016/j.celrep.2018.07.001
26. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-Genome Sequencing and Comprehensive Molecular Profiling Identify New Driver Mutations in Gastric Cancer. Nat Genet (2014) 46(6):573–82. doi: 10.1038/ng.2983
27. Kim M, Mun H, Sung CO, Cho EJ. Patient-Derived Lung Cancer Organoids as In Vitro Cancer Models for Therapeutic Screening. Nat Commun (2019) 10(1):3991. doi: 10.1038/s41467-019-11867-6
28. Lee SH, Hu W, Matalay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell (2018) 173(2):515–28.e17. doi: 10.1016/j.cell.2018.03.017
29. Sacha N, de Ligt J, Kopper O, Gogola E, Bouwona G, Weeber F, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell (2013) 153(2):373–81. doi: 10.1016/j.cell.2013.01.010

30. Huang L, Holzinger A, Jagan I, Begera M, Lohse I, Ngai N, et al. Ductal Pancreatic Cancer Modeling and Drug Screening Using Human Pluripotent Stem Cell- and Patient-Derived Tumor Organoids. Nat Med (2015) 21(11):1364–71. doi: 10.1038/nm.3973

31. Boi SF, Hwang C-I, Baker LA, Chio IIC, Engle DD, Corbo V, et al. Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell (2015) 160(1-2):324–38. doi: 10.1016/j.cell.2014.12.021

32. Driehuis E, Kolders S, Spelier S, Lõhmussaar K, Willems SM, Devriese LA, et al. Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Cancer Discov (2019) 9(7):852–71. doi: 10.1158/2326-7274.CD-18-1522

33. Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsai WY, et al. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. Cell Stem Cell (2018) 23(6):882–97.e11. doi: 10.1016/j.stem.2018.09.016

34. Calandrini C, Schutgens F, Oka R. An Organoid Biobank for Childhood Kidney Cancers That Captures Disease and Tissue Heterogeneity. Nat Commun (2020) 11(1):1310. doi: 10.1038/s41467-020-15155-6

35. Kondo T. Current Status and Future Outlook for Patient-Derived Cancer Models. From a Rare Cancer Research Perspective. Cancer Sci (2021) 112(3):953–61. doi: 10.1111/cas.14669

36. Colella G, Fazioli F, Gallo M, De Chiara A, Apice G, Russo C, et al. Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine. Int J Mol Sci (2018) 19(2):615. doi: 10.3390/ijms19020615

37. Zanoni M, Cortesi M, Zamagni A, Arienti C, Pignatta S, Tesei A. Modeling Three-Dimensional Patient-Derived Sarcoma Models: Promising Tools for Improving Clinical Tumor Management. Front Oncol (2017) 7:263. doi: 10.3389/fonc.2017.00263

38. Jin MZ, Jin WL. The Updated Landscape of Tumor Microenvironment and Drug Repurposing. Signal Transduct Targ Ther (2020) 5(1):166. doi: 10.1038/s41392-020-00280-x

39. Deepak KGK, Vempati R, Nagaraju GP, Dasari VR. NTumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer. Pharmacol Res (2020) 153:104683. doi: 10.1016/j.yphar.2020.104683

40. Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, et al. Development of a Patient-Derived Tumor Organoid Culture Model to Predict the Response in Glioblastoma. Cell Stem Cell (2018) 13(1):97. doi: 10.1016/s1094-5596(17)30222-0

41. Astashkina A, Grainger DW. Critical Analysis of 3-D Organoid In Vitro Cell Drug Screening Identi fl

42. Voges HK, Mills RJ, Elliott DA, Parton RG, Porrello ER, Hudson JE. Development of a Human Cardiac Organoid Injury Model Reveals Inmate Regenerative Potential. Development (2017) 144(6):1118–27. doi: 10.1242/dev.143966

43. Veressimo CS, Overmeer RM, Ponsioen B, Drost J, Mertens S, Verlaan-Klink I, et al. Targeting Mutant RAS in Patient-Derived Colorectal Cancer Organoids by Combinatorial Drug Screening. eLife (2016) 5:e18489. doi: 10.7554/eLife.18489

44. Whittle JR, Vaillant F. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res (2020) 26(15):4140–34. doi: 10.1158/1078-0432.crr-19-1872

45. Xiong G, Stewart RL. Collagen Prolifer 4-Hydroxysoflase 1 Is Essential for HIF-1α Stabilization and TNBC Chemoresistance. Nat Commun (2018) 9(1):4456. doi: 10.1038/s41467-018-06893-9

46. Schütte M, Risch T, Abbud-Azar N, Boehnke K, Schumacher D, Keil M, et al. Molecular Dissection of Colorectal Cancer in Pre-Clinical Models Identifies Biomarkers Predicting Sensitivity to EGFR Inhibitors. Nat Commun (2017) 8:14262. doi: 10.1038/ncomms14262

47. Tashiro T, Okuyama H, Endo H, Kawada K, Ashida Y, Ohue M, et al. In Vivo and Ex Vivo Cetuximab Sensitivity Assay Using Three-Dimensional Primary Culture System to Stratify KRAS Mutant Colorectal Cancer. PLoS ONE (2017) 12(6):e0174151. doi: 10.1371/journal.pone.0174151

48. Voges HK, Mills RJ, Elliott DA, Parton RG, Porrello ER, Hudson JE. Development of a Human Cardiac Organoid Injury Model Reveals Inmate Regenerative Potential. Development (2017) 144(6):1118–27. doi: 10.1242/dev.143966

49. Brandenberg N, Hoehnel S, Kuttler F. High-Throughput Screening in Colorectal Cancer Tissue-Originated Spheroids. Cancer Sci (2011) 100(3):345–55. doi: 10.1111/j.1349-7006.2010.01701.x

50. Verissimo CS, Overmeer RM, Ponsioen B, Drost J, Mertens S, Verlaan-Klink I, et al. Targeting Mutant RAS in Patient-Derived Colorectal Cancer Organoids by Combinatorial Drug Screening. eLife (2016) 5:e18489. doi: 10.7554/eLife.18489

51. Whittle JR, Vaillant F. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res (2020) 26(15):4140–34. doi: 10.1158/1078-0432.crr-19-1872

52. Xiong G, Stewart RL. Collagen Prolifer 4-Hydroxysoflase 1 Is Essential for HIF-1α Stabilization and TNBC Chemoresistance. Nat Commun (2018) 9(1):4456. doi: 10.1038/s41467-018-06893-9

53. Schütte M, Risch T, Abbud-Azar N, Boehnke K, Schumacher D, Keil M, et al. Molecular Dissection of Colorectal Cancer in Pre-Clinical Models Identifies Biomarkers Predicting Sensitivity to EGFR Inhibitors. Nat Commun (2017) 8:14262. doi: 10.1038/ncomms14262

54. Tashiro T, Okuyama H, Endo H, Kawada K, Ashida Y, Ohue M, et al. In Vivo and Ex Vivo Cetuximab Sensitivity Assay Using Three-Dimensional Primary Culture System to Stratify KRAS Mutant Colorectal Cancer. PLoS ONE (2017) 12(6):e0174151. doi: 10.1371/journal.pone.0174151

55. Kasuta T, Kawamata M, Hagiwara K, Takashashi RU, Yamamoto Y, Camargo FD, et al. Conversion of Terminally Committed Hepatocytes to Culturable Bipotent Progenitor Cells With Regenerative Capacity. Cell Stem Cell (2017) 20(1):51–55. doi: 10.1016/j.stem.2017.10.010

56. Eder A, Vollert L, Hansen A, Eschenhagen T. Human Engineered Heart Tissue as a Model System for Drug Testing. Adv Drug Deliv Rev (2016) 96:214–24. doi: 10.1016/j.addr.2015.05.010
Brain Network Development. *Cell Stem Cell* (2019) 25(4):558–69.e7. doi: 10.1016/j.stem.2019.08.002

106. Reardon S. Can Lab-Grown Brains Become Conscious? *Nature* (2020) 586 (7831):658–61. doi: 10.1038/d41586-020-02986-y

107. Pašća SP. The Rise of Three-Dimensional Human Brain Cultures. *Nature* (2018) 553(7689):437–45. doi: 10.1038/nature25032

108. Hyun I, Scharf-Deering JC, Lunshof JE. Ethical Issues Related to Brain Organoid Research. *Brain Res* (2020) 1732:146653. doi: 10.1016/j.brainres.2020.146653

109. Dickreuter E, Cordes N. The Cancer Cell Adhesion Resistome: Mechanisms, Targeting and Translational Approaches. *Biol Chem* (2017) 398(7):721–35. doi: 10.1515/hsz-2016-0326

110. Fang Y, Eglen RM. Three-Dimensional Cell Cultures in Drug Discovery and Development. *SLAS Discov Advancing Life Sci R D* (2017) 22(5):456–72. doi: 10.1177/1087057117696795

111. Katt ME, Placone AL, Wong AD, Xu ZS, Searson PC. *In Vitro* Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. *Front Bioeng Biotechnol* (2016) 4:12. doi: 10.3389/fbioe.2016.00012

112. Fennema E, Rivron N, Rouwkema J, van Blitterswijk C, de Boer J. Spheroid Culture as a Tool for Creating 3D Complex Tissues. *Trends Biotechnol* (2013) 31(2):108–15. doi: 10.1016/j.tibtech.2012.12.003

113. Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T, Okamoto K. Tumor-Derived Spheroids: Relevance to Cancer Stem Cells and Clinical Applications. *Cancer Sci* (2017) 108(3):283–9. doi: 10.1111/cas.13155

114. Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid Technology and Applications in Cancer Research. *J Hematol Oncol* (2018) 11(1):116. doi: 10.1186/s13045-018-0662-9

115. Fiorini E, Veghini L, Corbo V. Modeling Cell Communication in Cancer With Organoids: Making the Complex Simple. *Front Cell Dev Biol* (2020) 8:166. doi: 10.3389/fcell.2020.00166

116. Nunes AS, Barros AS, Costa EC, Moreira AF, Correia JI. 3D Tumor Spheroids as *In Vitro* Models to Mimic *In Vivo* Human Solid Tumors Resistance to Therapeutic Drugs. *Biomater Sci* (2019) 116: (1):206–26. doi: 10.1002/biot.26845

117. Gilazieva Z, Ponomarev A, Rutland C. Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine. *Cancers* (2020) 12 (10):2727. doi: 10.3390/cancers12102727

118. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. *N Engl J Med* (2012) 366(10):883–92. doi: 10.1056/NEJMoa1113205

119. Nozaki K, Mochizuki W, Matsumoto Y, Matsumoto T, Fukuda M, Mizutani T, et al. Co-Culture With Intestinal Epithelial Organoids Allows Efficient Expansion and Motility Analysis of Intraepithelial Lymphocytes. *J Gastroenterol* (2016) 51(3):206–13. doi: 10.1007/s00535-016-1170-8

120. DiMarco RL, Dewi RE, Bernal G, Kuo C, Heilshorn SC. Protein-Engineered Scaffolds for *In Vitro* 3D Cultures of Primary Adult Intestinal Organoids. *Biomater Sci* (2015) 3(10):1736–85. doi: 10.1039/c5bm00108k

121. Gunasekara DB, DiSalvo M, Wang Y, Nguyen DL, Reed MI, Speer J, et al. Development of Arrayed Colonic Organoids for Screening of Secretagogues Associated With Enterotoxins. *Anal Chem* (2018) 90(3):1941–50. doi: 10.1021/acs.analchem.7b04032

122. Francies HE, Barthorpe A, McLaren-Douglas A, Barendt WJ, Garnett MJ. Drug Sensitivity Assays of Human Cancer Organoid Cultures. *Methods Mol Biol* (2019) 1576:339–51. doi: 10.1007/7651_2016_10

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhou, Cong and Cong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.